Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.72 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.72 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL1B | P01584 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106064 | 1.00 | DDB1 (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22794178 | 1.00 | DDB1 (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25108796 | 0.91 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22225435 | 0.90 | CRBN (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23895935 | 0.90 | CRBN (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25109951 | 0.89 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25467701 | 0.88 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18878464 | 0.88 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25467690 | 0.88 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30011404 | 0.87 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064358-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024035780-A1 | AKR1C3 TARGETED HETEROBIFUNCTIONAL SMALL MOLECULE PROTEOLYSIS TARGETING CHIMERAS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| WO-2017046036-A1 | COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | DDB1 313/4885CRBN 151/4885IKZF3 231/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | DDB1 3423/4885CRBN 3449/4885IKZF3 4014/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | DDB1 333/4885CRBN 154/4885IKZF3 653/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | DDB1 3423/4885CRBN 3449/4885IKZF3 4014/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | DDB1 134/4885CRBN 520/4885IKZF3 1083/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | DDB1 987/4885CRBN 179/4885IKZF3 1442/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | DDB1 55/4885CRBN 1187/4885IKZF3 2102/4885 |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | DDB1 418/4885CRBN 195/4885IKZF3 270/4885 |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | DDB1 68/4885CRBN 605/4885IKZF3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.